Pharmaceutical and Bio Industry Expected to Recover Investor Sentiment Starting Next Month

[Asia Economy Reporter Hyungsoo Park] Although the pharmaceutical and bio sectors have been sluggish this year, there is a forecast that they will attract attention starting next month.

Seon Minjeong, a researcher at Hana Financial Investment, stated on the 21st, "Investment sentiment in the pharmaceutical and bio sectors is expected to recover next month," and explained, "We anticipate the listing of notable companies and a rebound in related stock prices."

She continued, "SK Bioscience will be listed around mid-next month," adding, "market interest is expected to grow due to expectations for COVID-19 vaccine contract manufacturing."

Additionally, she emphasized, "We expect a revaluation of companies related to vaccine contract manufacturing," and "NeoImmuneTech, a new drug development company, will be listed around mid-next month."

She further noted, "Starting from April, major conferences related to anticancer drugs will be held," and "momentum will be secured for anticancer drug and new drug development companies scheduled to announce clinical results at these conferences."

She stated, "The pharmaceutical and bio sectors, which have been sluggish since December last year, are expected to see a full recovery in investment sentiment as companies with high market interest get listed and the conference season begins next month."

This content was produced with the assistance of AI translation services.